Santhera Strengthens Executive Team With Appointment Of Marc Clausse, Former Mirum VP

Santhera Pharmaceuticals has announced the appointment of Marc Clausse as its new Chief Commercial Officer (CCO), effective June 1, 2026. He will take over from Geert Jan van Daal, who is retiring after more than a decade with the company. Although he is stepping down, Geert Jan will continue to support the organization for the next few months to ensure a smooth and well-coordinated transition.

Marc Clausse joins Santhera with over 25 years of international experience in the life sciences industry. Over the course of his career, he has worked extensively across specialty medicines, oncology and rare diseases, building a reputation for strong commercial leadership and the ability to scale high-performing teams. His background includes leading complex global organizations and driving sustained commercial growth in both emerging biotech environments and established pharmaceutical companies. Marc has also built deep expertise in European market access, pricing and reimbursement, and strategic partnership management—all areas that will be valuable as Santhera continues to expand.

Most recently, Marc served as Vice President of International Strategy & Operations and UK General Manager at Mirum Pharmaceuticals. In this role, he played a central part in shaping and executing the company’s international strategy. He co-led the development of regional commercial structures, acted as a key decision-maker in market access and pricing negotiations, and established distributor partnerships across Europe and other international markets. Under his leadership, the organization regularly exceeded its revenue targets during multiple product launches, demonstrating his ability to deliver strong commercial results in competitive therapeutic areas.

Before that, Marc held senior roles in oncology. He served as VP and Oncology Head for the UK and Ireland at GSK, where he oversaw the ovarian cancer portfolio and led it to a leading position in the market. During this time, he also managed the integration of Tesaro in the UK following its acquisition in 2018. Earlier, as General Manager for Tesaro in the UK and Ireland, he was responsible for all commercial, medical and market access functions. He established key reimbursement pathways and built an organizational foundation that supported sustained regional growth.

As he steps into his new role, Marc succeeds Geert Jan van Daal, who has been an important part of Santhera’s commercial leadership since joining the company in 2015. Geert Jan initially served as General Manager for France and Benelux and later expanded his responsibilities to include Iberia, the UK and Ireland, and the broader Western European region. In January 2024, he was appointed Chief Commercial Officer and played a pivotal role in the European launch of AGAMREE (vamorolone). Under his leadership, Santhera significantly increased patient access across and beyond its key markets.

Santhera’s Chief Executive Officer, Dario Eklund, expressed his gratitude for Geert Jan’s contributions and acknowledged his role in bringing AGAMREE to patients across Europe. He also welcomed Marc to the executive team, noting that the company is entering an important phase of growth. Dario highlighted that Marc’s experience and leadership will be instrumental as Santhera strengthens its commercial platform, expands internationally and continues evolving its product portfolio to deliver long-term value for both patients and shareholders.

Marc Clausse said he is pleased to be joining Santhera at such a meaningful time. He emphasized that AGAMREE represents an important advancement for individuals living with Duchenne muscular dystrophy and expressed his enthusiasm for working with Dario and the broader team to expand global access to the therapy while supporting the company’s strategic growth initiatives. Reflecting on his departure, Geert Jan van Daal shared that it has been a privilege to contribute to Santhera’s mission and to help bring new treatment options to patients with significant unmet medical needs. He also noted that he looks forward to assisting with the transition and supporting the team as they move into this next chapter.